Sector News

The eyes have it as Shire parades pipeline

December 11, 2014
Life sciences
Shire, fresh from the collapse of its $55 billion takeover by AbbVie, has been touting its pipeline to investors in the USA, highlighting treatments which could contribute $3 billion in sales by 2020.
 
Speaking to investors at Shire’s US headquarters in Lexington, Massachusetts, chief executive Flemming Ornskov said that there were 22 programmes in the clinic, “the most in Shire’s history”. R&D head Philip Vickers added that “a number of significant clinical milestones [are] anticipated over the next 18 months”, saying the “highly productive internal pipeline” will be “complemented by the acquisition of external assets and innovative collaborations”.
 
Chief among these treatments is SHP607, a protein replacement therapy which has just received fast-track designation from the the US Food and Administration for the prevention of retinopathy of prematurity, a blinding eye disorder that affects premature babies. It is currently in Phase II.
 
Staying with things ocular, lifitegrast for dry eye disease will be filed in the first quarter of 2015. Shire also highlighted SHP625 for the rare genetic disorder Alagille Syndrome and SHP626  for non-alcoholic steatohepatitis, a condition characterized by fat deposits in the liver. The company also has an action date of February 1 for its attention-deficit hyperactivity disorder blockbuster Vyvanse (lisdexamfetamine dimesylate) as a potential treatment for binge eating disorder.
 
CF project
 
Shire also announced that it is receiving up to $15 million from the Cystic Fibrosis Foundation to support its messenger RNA technology platform for the disease.  
 
The company said its goal is to deliver mRNA that codes for a fully functional version of the cystic fibrosis transmembrane conductance (CFTR) protein to the lungs of CF patients. If high enough levels of functional CFTR protein can be produced, lung function may be improved.
 
By Kevin Grogan
 
Source: Pharma Times

comments closed

Related News

October 17, 2021

Colorcon acquires a majority share in Ideal Cures Pvt. Ltd., India

Life sciences

Ideal Cures will operate as a fully independent entity within Colorcon. Their business complements Colorcon’s position in the Indian pharmaceutical market with a strong presence in the domestic generic sector comprised of long-standing customer relationships sustained by innovative and customized solutions.

October 17, 2021

Barriers exist, but participation urgent in breast cancer clinical trials: report

Life sciences

Across four new breast cancer treatments approved by the FDA last year, 2% to 9% of patients in clinical trials for the drugs were Black Americans and 0% to 9% were Hispanic, according to a new report from Breastcancer.org.

October 17, 2021

Danish consortium acquires part of Jernbanebyen to create one of the world’s healthiest urban villages

Life sciences

The southern section of Jernbanebyen in central Copenhagen has a new owner. The Baneby Consortium, comprising NREP, Novo Holdings and Industriens Pension, has bought the land from Freja Ejendomme. The ambition is to create a green, partly car-free environment that will also be one of the healthiest in the world. 

Send this to a friend